{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:48:34Z","timestamp":1778622514847,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Cancer precision medicine is an effective strategy to fight cancers by bridging genomics and drug discovery to provide specific treatment for patients with different genetic characteristics. Although some public databases and modelling frameworks have been developed through studies on drug response, most of them only considered the ramifications of the drug on the cell line and the effects on the patient still require a huge amount of work to integrate data from various databases and calculations, especially concerning precision treatment. Furthermore, not only efficacy but also the adverse effects of drugs on patients should be taken into account during cancer treatment. However, the adverse effects as essential indicators of drug safety assessment are always neglected.<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> A holistic estimation explores various drugs\u2019 efficacy levels by calculating their potency both in reversing and enhancing cancer-associated gene expression change. And a method for bridging the gap between cell culture and living tissue estimates the effectiveness of a drug on individual patients through the mappings of various cell lines to each person according to their genetic mutation similarities.<\/jats:p><jats:p><jats:bold>Result:<\/jats:bold> We predicted the efficacy of FDA-recommended drugs, taking into account both efficacy and toxicity, and obtained consistent results. We also provided an intuitive and easy-to-use web server called DBPOM (<jats:ext-link>http:\/\/www.dbpom.net\/<\/jats:ext-link>, a comprehensive database of pharmaco-omics for cancer precision medicine), which not only integrates the above methods but also provides calculation results on more than 10,000 small molecule compounds and drugs. As a one-stop web server, clinicians and drug researchers can also analyze the overall effect of a drug or a drug combination on cancer patients as well as the biological functions that they target. DBPOM is now public, free to use with no login requirement, and contains all the data and code.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Both the positive and negative effects of drugs during precision treatment are essential for practical application of drugs. DBPOM based on the two effects will become a vital resource and analysis platform for drug development, drug mechanism studies and the discovery of new therapies.<\/jats:p>","DOI":"10.3389\/fphar.2023.1085765","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T06:22:13Z","timestamp":1673504533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Yijun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuhu","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"16022","DOI":"10.1038\/ncomms16022","article-title":"Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets","volume":"8","author":"Chen","year":"2017","journal-title":"Nat. Commun."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1038\/s41467-019-09692-y","article-title":"Publisher Correction: Network-based prediction of drug combinations","volume":"10","author":"Cheng","year":"2019","journal-title":"Nat. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/cgt.2013.13","article-title":"Predictive molecular pathology and its role in targeted cancer therapy: A review focussing on clinical relevance","volume":"20","author":"Dietel","year":"2013","journal-title":"Cancer gene Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene expression omnibus: Ncbi gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic acids Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4233s","DOI":"10.1158\/1078-0432.CCR-040005","article-title":"The role of gefitinib in lung cancer treatment","volume":"10","author":"Giaccone","year":"2004","journal-title":"Clin. cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1377\/hlthaff.2017.1624","article-title":"Precision medicine: From science to value","volume":"37","author":"Ginsburg","year":"2018","journal-title":"Health Aff."},{"key":"B9","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa031644","article-title":"Cisplatin-based adjuvant chemotherapy in patients with completely resected non\u2013small-cell lung cancer","volume":"350","author":"Group","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1208\/s12248-012-9432-8","article-title":"Therapeutic roles of curcumin: Lessons learned from clinical trials","volume":"15","author":"Gupta","year":"2013","journal-title":"AAPS J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/toxsci\/kfh145","article-title":"Gene expression profiling of rat livers reveals indicators of potential adverse effects","volume":"80","author":"Heinloth","year":"2004","journal-title":"Toxicol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13046-015-0171-4","article-title":"T-type calcium channel antagonists, mibefradil and nnc-55-0396 inhibit cell proliferation and induce cell apoptosis in leukemia cell lines","volume":"34","author":"Huang","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"Synergyfinder 2.0: Visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"","journal-title":"Nucleic acids Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1007604","DOI":"10.1371\/journal.pcbi.1007604","article-title":"Syntoxprofiler: An interactive analysis of drug combination synergy, toxicity and efficacy","volume":"16","author":"Ianevski","year":"","journal-title":"PLoS Comput. Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1038\/s41467-020-18742-9","article-title":"Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy","volume":"11","author":"Jing","year":"2020","journal-title":"Nat. Commun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for rna-seq data with deseq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-11-2197","article-title":"Vemurafenib and BRAF inhibition: A new class of treatment for metastatic melanoma","volume":"18","author":"Luke","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","article-title":"Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines","volume":"83","author":"Monks","year":"1991","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"B19","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/bib\/bbz140","article-title":"A survey on adverse drug reaction studies: Data, tasks and machine learning methods","volume":"22","author":"Nguyen","year":"2021","journal-title":"Briefings Bioinforma."},{"key":"B20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.lungcan.2009.06.006","article-title":"Pemetrexed in the treatment of advanced non-squamous lung cancer","volume":"66","author":"Rossi","year":"2009","journal-title":"Lung cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1158\/1535-7163.MCT-14-0260","article-title":"Cancer in silico drug discovery: A systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes","volume":"13","author":"San Lucas","year":"2014","journal-title":"Mol. cancer Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","article-title":"A next generation connectivity map: L1000 platform and the first 1, 000, 000 profiles","volume":"171","author":"Subramanian","year":"2017","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"5690","DOI":"10.1158\/0008-5472.CAN-13-3540","article-title":"Novel drug candidates for the treatment of metastatic colorectal cancer through global inverse gene-expression profiling","volume":"74","author":"van Noort","year":"2014","journal-title":"Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/bib\/bbw048","article-title":"The role of drug profiles as similarity metrics: Applications to repurposing, adverse effects detection and drug\u2013drug interactions","volume":"18","author":"Vilar","year":"2017","journal-title":"Briefings Bioinforma."},{"key":"B25","article-title":"Challenges pertaining to adverse effects of drugs","volume":"9","author":"Wakaskar","year":"2017","journal-title":"Int. J. Drug Dev. Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.mayocp.2017.09.001","article-title":"Pharmacogenomics: Precision medicine and drug response","volume":"92","author":"Weinshilboum","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The cancer genome atlas pan-cancer analysis project","volume":"45","author":"Weinstein","year":"2013","journal-title":"Nat. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.tips.2020.10.004","article-title":"Single-cell techniques and deep learning in predicting drug response","volume":"41","author":"Wu","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/0008-5472.CAN-11-2941","article-title":"Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer","volume":"72","author":"Yang","year":"","journal-title":"Cancer Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of drug sensitivity in cancer (gdsc): A resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"","journal-title":"Nucleic acids Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/bioinformatics\/btv313","article-title":"Dsigdb: Drug signatures database for gene set analysis","volume":"31","author":"Yoo","year":"2015","journal-title":"Bioinformatics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.ccell.2020.10.008","article-title":"Large-scale characterization of drug responses of clinically relevant proteins in cancer cell lines","volume":"38","author":"Zhao","year":"2020","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1085765\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T06:22:15Z","timestamp":1673504535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1085765\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":32,"alternative-id":["10.3389\/fphar.2023.1085765"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1085765","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]},"article-number":"1085765"}}